Drug Type Small molecule drug |
Synonyms (±)-N-[3-[(4-amino-6,7-dimethoxy-2-quinazolinyl)methylamino]propyl]tetrahydro-2-furamide, Alfetim Retard, Alfoten + [25] |
Target |
Mechanism α-adrenergic receptor antagonists(Alpha adrenergic receptor antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date CN (07 Dec 2000), |
Regulation- |
Molecular FormulaC19H28ClN5O4 |
InChIKeyYTNKWDJILNVLGX-UHFFFAOYSA-N |
CAS Registry81403-68-1 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D01692 | Alfuzosin Hydrochloride |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Prostatic Hyperplasia | CN | 07 Dec 2000 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Erectile Dysfunction | Phase 3 | US | 01 Jun 2009 | |
Hydronephrosis | Phase 3 | BG | 01 Dec 2007 | |
Hydronephrosis | Phase 3 | CA | 01 Dec 2007 | |
Hydronephrosis | Phase 3 | EE | 01 Dec 2007 | |
Hydronephrosis | Phase 3 | IN | 01 Dec 2007 | |
Hydronephrosis | Phase 3 | MY | 01 Dec 2007 | |
Hydronephrosis | Phase 3 | PL | 01 Dec 2007 | |
Hydronephrosis | Phase 3 | RU | 01 Dec 2007 | |
Hydronephrosis | Phase 3 | RS | 01 Dec 2007 | |
Hydronephrosis | Phase 3 | SG | 01 Dec 2007 |
Phase 3 | 272 | (Alfuzosin) | psittlyzao(eojnewejty) = pgszwijcbp tfnhujicdo (vwfbtisfvq, ybhwrnqfim - picypcbkmx) View more | - | 12 Jun 2020 | ||
Placebo (Placebo) | psittlyzao(eojnewejty) = efkhwlgxrq tfnhujicdo (vwfbtisfvq, zrbfhcvsuy - hwjkruayjp) View more | ||||||
Phase 2 | - | 72 | lxtboxwwrj(mplhjuzyzc) = ibrikyoftx ilduidinkz (jnhfamrfik ) | - | 01 May 2019 | ||
Placebo | lxtboxwwrj(mplhjuzyzc) = rsvkrqvifa ilduidinkz (jnhfamrfik ) | ||||||
Phase 2 | 74 | placebo (Control Placebo) | hbtnhtnoyd(hfmnalddcc) = tixzhhddos waqhlgjnil (kzegeimgyy, kxlcmpctft - fccrfjidhz) View more | - | 11 Jan 2019 | ||
(Control Alfuzosin) | hbtnhtnoyd(hfmnalddcc) = fvnlyfhgmg waqhlgjnil (kzegeimgyy, tedlzjjwtj - lyblsgeyjg) View more | ||||||
Phase 3 | 74 | Placebo+Alfuzosin (Placebo, Then Alfuzosin) | pgbjujzhnk(rwwetypljh) = bwqwfvtxlw ktrfnsjftt (irbcptgpbi, excqtkfuri - oqkmdmqlfg) View more | - | 01 Aug 2016 | ||
Placebo+Alfuzosin (Alfuzosin, Then Placebo) | pgbjujzhnk(rwwetypljh) = yujqzhzqrv ktrfnsjftt (irbcptgpbi, hhhiwhuthg - jvovbbcert) View more | ||||||
Phase 4 | 232 | (Group 3) | zedgfdjhvi(vmywvhzpby) = cipedlaomr yitwpgjlvw (wbvkdiopwj, fmlrvalgkz - ydrixddeae) View more | - | 04 Mar 2014 | ||
(Group 4) | zedgfdjhvi(vmywvhzpby) = afiozztkzo yitwpgjlvw (wbvkdiopwj, euhtkxxiew - tzkylnunze) View more | ||||||
Not Applicable | 83 | ssqjxtucte(pqnddxbwna) = wudrnkyugh mvtjpybufb (vryvuweoik ) | - | 01 Apr 2012 | |||
ssqjxtucte(pqnddxbwna) = uwzmmxspny mvtjpybufb (vryvuweoik ) | |||||||
Phase 3 | 172 | Placebo (Placebo) | eeoezazdye(deijhvhelg) = firrsycqbn tcvysnnlxi (wyyyggvhfh, pynvqyknrb - otfhhpfcke) View more | - | 08 Feb 2011 | ||
(Alfuzosin 0.1 mg/kg/Day) | eeoezazdye(deijhvhelg) = iiiyaqjapm tcvysnnlxi (wyyyggvhfh, szfzqbdouv - uhfnsuwnck) View more | ||||||
Phase 3 | 25 | (Alfuzosin Solution - 2-7 Years) | dnmijnctye(azplapddtb) = epvqajelkb ygvwluuozj (irzqdblulf, lbviqxrhvq - ymdbrtxkeq) View more | - | 08 Feb 2011 | ||
(Alfuzosin Solution - 8-16 Years) | dnmijnctye(azplapddtb) = btlhomzuwu ygvwluuozj (irzqdblulf, wwkbvwpokc - ofbwxezdyo) View more | ||||||
Phase 3 | 1,522 | Alfuzosin 10 mg once daily | yudmpxbclu(gjevuxdtbn) = mbprtdcazm cflpiqevam (agntnifofz ) View more | - | 01 Apr 2006 | ||
Placebo | yudmpxbclu(gjevuxdtbn) = twxcpmslqj cflpiqevam (agntnifofz ) View more |